Abacavir+Lamivudine Suppliers & Bulk Manufacturers
Available Forms: Tablets / Oral solution
Available Strengths: 600mg+300mg
Reference Brands: Epzicom (USA), Kivexa(USA/EU), Ziagen (USA/EU)
Category: Anti Viral
Abacavir/Lamivudine is a fixed-dose antiretroviral combination used in the treatment of HIV-1 infection. It combines two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the reverse transcriptase enzyme, preventing viral replication and reducing viral load in patients. Abacavir+Lamivudine is available in Tablets / Oral solution and strengths such as 600mg+300mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Abacavir+Lamivudine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Abacavir+Lamivudine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Abacavir and Lamivudine are used together as part of combination antiretroviral therapy for the treatment of HIV-1 infection. This fixed-dose combination helps lower viral load, improve immune function, and reduce the progression of HIV when used with other antiretroviral medicines.
This combination contains two active ingredients: abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) that blocks viral DNA chain elongation, and lamivudine, another NRTI that interferes with viral replication by inhibiting reverse transcriptase. Together, they provide dual NRTI backbone coverage.
The most recognized international trade names for this combination are Kivexa and Epzicom. Several generic brands also exist in different markets.
Kivexa and Epzicom are manufactured by ViiV Healthcare, a joint venture of GSK, Pfizer, and Shionogi.
The generic name of the product is abacavir and lamivudine.
Common brand names include Kivexa and Epzicom, along with various generic versions depending on the region.
Abacavir and Lamivudine combination products (Kivexa/Epzicom) are manufactured by ViiV Healthcare in its approved global facilities. Generic formulations are widely produced in India and other countries by licensed pharmaceutical manufacturers based on regulatory approvals.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
